国产长春瑞滨不同联合化疗方案治疗晚期非小细胞肺癌的临床研究

Clinical Study with Vinorelbine Combined Cisplatin and Etoposide or Ifosfamide in the Treatment of Advanced Non Small Cell Lung Cancer

目的 :研究以国产长春瑞滨 (VNLB盖诺 )为主的不同联合化疗方案治疗晚期非小细胞肺癌的临床疗效及其毒性反应。方法 :选择 73例不能手术的Ⅲb～Ⅳ期非小细胞肺癌病人 ,随机分为 3组 ,分别采用NP方案、INP方案及VNP方案治疗。结果 :INP方案有效率为 6 0 % ,中位生存期为 5 6周 ;似高于NP及VNP方案。但统计学上无明显差异 (P >0 0 5 )。结论 :盖诺与顺铂、异环磷酰胺或VP 16联合治疗晚期非小细胞肺癌 (NSCLC)疗效好 。

Objective:Vinorelbine(VNLB) that was made in China was mainly combined different chemotherapy project to study their side effect and curative effect in treatment of advanced non small cell lung cancer(NSCLC).Methods:Seventy three patients who had lost chance for operation with stage Ⅲb to stage Ⅳ NSCLC were divided randomly into three groups, and they accepted treatment with NP?INP and VNP respectively.Results:A effective rate of treated by INP group was 60% and the median survival was 56 weeks which seems more than that of NP and VNP groups. But no obvious difference on statistics was observed between them (P>0 05).Conclusion:Vinorelbine combined cisplatin?etoposide or ifosfamide had got better curative effect in the treatment of advanced non small cell lung cancer. Although it has toxicity, it can be tolerated.